BMRN
Market read
The latest filing is mixed. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 25 directly disclosed connections are confirming.
Invalidation: The isolated read changes if BMRN's group or a disclosed connection begins moving with it.
Research brief
The latest filing is mixed. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 25 directly disclosed connections are confirming.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“These increases were partially offset by the following: 27 Table of Contents Management’s Discussion and Analysis of Financial Condition and Results of Operations (continued) (In millions of U.S.”10-Q · Aug 6, 2026 ↗
“5 Change Favorable (unfavorable) impact of foreign currency exchange rates on product sales denominated in currencies other than USD $ 6.6 $ (7.1) $ 13.7 $ 15.3 $ (20.7) $ 36.0 The favorable impact for the three and six months ended June 30, 2026 was primaril…”10-Q · Aug 6, 2026 ↗
“The increase in G&A expense for the three and six months ended June 30, 2026 as compared to the three and six months ended June 30, 2025 was primarily due to integration and restructuring charges related to the acquisition of Amicus and incremental administra…”10-Q · Aug 6, 2026 ↗
“We expect Interest expense to increase over the next 12 months due to long-term debt financings completed in 2026.”10-Q · Aug 6, 2026 ↗
Valuation discipline
Price/sales 4.0× · EV/sales 3.6×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for BMRN. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment
10-Q filed 2026-08-06 against the comparable filing from 2025-08-05.
Capital and cash conversion
Capital spending consumed more revenue while free-cash-flow margin declined.
Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.
“Cost of sales increased and Gross margin decreased in the six months ended June 30, 2026 as compared to the six months ended June 30, 2025, primarily due to an increase in sales volume, a $31.0 million charge recorded in first quarter of 2026 associated with an unsuccessful process qualification campaign to expand NAGLAZYME manufacturing capabilities, and amortization of acquired inventory fair value step-up.”
“The increase in G&A expense for the three and six months ended June 30, 2026 as compared to the three and six months ended June 30, 2025 was primarily due to integration and restructuring charges related to the acquisition of Amicus and incremental administrative costs related to ongoing support of corporate initiatives.”
“The following table shows our Net Product Revenues denominated in USD and foreign currencies: Three Months Ended June 30, Six Months Ended June 30, 2026 2025 Change 2026 2025 Change Sales denominated in USD $ 488.3 $ 403.1 $ 85.2 $ 851.0 $ 762.0 $ 89.0 Sales denominated in foreign currencies 496.1 409.9 86.2 893.5 785.6 107.9 Total net product revenues $ 984.4 $ 813.0 $ 171.4 $ 1,744.5 $ 1,547.6 $ 196.9 Three Months Ended June 30, Six Months Ended June 30, 2026 2025 Change 2026 2025 Change Favorable (unfavorable) impact of foreign currency exchange rates on product sales denominated in currencies other than USD $ 6.6 $ (7.1) $ 13.7 $ 15.3 $ (20.7) $ 36.0 The favorable impact for the three a...”
Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
“1 to License Agreement between Sarepta Therapeutics, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 28 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
BMRN is currently a Leader in the organic co-movement group Rare Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for BMRN; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.